KORU Medical Systems (NASDAQ:KRMD) Issues Earnings Results

KORU Medical Systems (NASDAQ:KRMD) issued its quarterly earnings data on Wednesday. The company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03, Zacks reports. KORU Medical Systems had a negative return on equity of 13.61% and a negative net margin of 5.27%.The firm had revenue of $12.05 million during the quarter, compared to analyst estimates of $11.62 million.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q2 revenue reached a record $12 million, up 18% year over year, driven by 12% growth in domestic core revenue and 59% international growth. Management said domestic demand, patient retention, new starts, and market-share gains remain strong.
• Gross margin improved to 65.1% from 63.5% a year ago, supported by manufacturing efficiencies, pricing, mix, and improved supplier terms. KORU also reported positive net income for the first time since 2019, positive operating cash flow in the quarter, and reiterated expectations for positive adjusted EBITDA for the full year.
• The company narrowed 2026 revenue guidance to $47.5 million-$48.5 million from its prior outlook, citing slower-than-expected launches in certain international, non-tender markets. Management now expects some of that prefilled-syringe opportunity to contribute more meaningfully in 2027.
• KORU withdrew its U.S. PHESGO 510(k) application after discussions with the FDA and will pursue other oncology biologics instead, delaying its planned U.S. oncology entry. PHESGO remains part of the international strategy, but additional real-world evidence and regulatory work are required.
• The company acquired connected-monitoring technology intended to add adherence tracking, real-world evidence, and patient support to its infusion platform, though management characterized it as a multi-year development effort. KORU also said Freedom 360 development has cleared its highest-risk stages and remains on track for a U.S. 510(k) submission by the end of 2027.

KORU Medical Systems Price Performance

Shares of KORU Medical Systems stock traded down $0.57 during trading hours on Thursday, reaching $3.56. The company had a trading volume of 1,075,072 shares, compared to its average volume of 166,755. The firm has a market cap of $163.52 million, a PE ratio of -71.20 and a beta of 0.45. KORU Medical Systems has a one year low of $3.21 and a one year high of $6.61. The business has a fifty day simple moving average of $4.12 and a 200 day simple moving average of $4.37.

Insider Transactions at KORU Medical Systems

In related news, insider Adam R. Kalbermatten bought 12,500 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was acquired at an average price of $3.94 per share, for a total transaction of $49,250.00. Following the purchase, the insider directly owned 312,500 shares in the company, valued at $1,231,250. This trade represents a 4.17% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders bought 28,000 shares of company stock worth $109,430. Corporate insiders own 18.50% of the company’s stock.

Hedge Funds Weigh In On KORU Medical Systems

A number of large investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in KORU Medical Systems by 52.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after purchasing an additional 3,478 shares during the period. Lazard Asset Management LLC purchased a new position in KORU Medical Systems during the second quarter worth about $59,000. Acadian Asset Management LLC purchased a new position in KORU Medical Systems during the first quarter worth about $63,000. Invesco Ltd. bought a new position in KORU Medical Systems in the 2nd quarter worth about $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of KORU Medical Systems in the 2nd quarter valued at about $83,000. 58.60% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on KRMD shares. Craig Hallum reiterated a “buy” rating and issued a $6.00 target price on shares of KORU Medical Systems in a research note on Thursday. Weiss Ratings raised shares of KORU Medical Systems from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen upgraded shares of KORU Medical Systems from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.00.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.